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ABSTRACT
We report that combining a DNA analog (20F-ANA)
with rigid RNA analogs [20F-RNA and/or locked
nucleic acid (LNA)] in siRNA duplexes can produce
gene silencing agents with enhanced potency. The
favored conformations of these two analogs are dif-
ferent, and combining them in a 1–1 pattern led to
reduced affinity, whereas alternating short continu-
ous regions of individual modifications increased
affinity relative to an RNA:RNA duplex. Thus, the
binding affinity at key regions of the siRNA duplex
could be tuned by changing the pattern of incorpor-
ation of DNA-like and RNA-like nucleotides. These
heavily or fully modified duplexes are active against
a range of mRNA targets. Effective patterns of modi-
fication were chosen based on screens using two
sequences targeting firefly luciferase. We then
applied the most effective duplex designs to the
knockdown of the eIF4E binding proteins 4E-BP1
and 4E-BP2. We identified modified duplexes with
potency comparable to native siRNA. Modified
duplexes showed dramatically enhanced stability to
serum nucleases, and were characterized by circular
dichroism and thermal denaturation studies.
Chemical modification significantly reduced the
immunostimulatory properties of these siRNAs in
human peripheral blood mononuclear cells.
INTRODUCTION
RNA interference (RNAi), an endogenous gene silencing
process, can be triggered by dsRNA to elicit speciﬁc gene
silencing (1). The discovery that 21-nt siRNAs act as ex-
ogenous synthetic triggers of RNAi in mammalian cells (2)
incited rapid development of siRNA-based therapeutic
candidates. Yet the fact remains that siRNAs are not
ideal drug candidates. Cellular uptake of siRNA is poor,
rapid nuclease-mediated degradation in vivo reduces
duration of activity, and oﬀ-target eﬀects (OTEs) arising
from partial complementarity to unintended genes and
nonspeciﬁc immune responses to siRNAs are important
considerations for the clinical development of siRNA
therapeutics. A variety of chemical modiﬁcations have
been developed to address these issues (3). In some
cases, modiﬁcation of siRNA leads to increased activity.
However, patterns of modiﬁcation are typically heavily
sequence dependent, forcing optimization of the modiﬁca-
tion strategy for each diﬀerent siRNA sequence and
target. A universally active heavily modiﬁed siRNA
design has thus far proven elusive but remains an attract-
ive goal. We have argued that siRNA designs comprising
combinations of chemical modiﬁcations are more likely to
achieve this goal (3,4).
When siRNA is introduced into mammalian cells, it is
recognizedbythe RNA-induced silencing complex(RISC),
a multiprotein complex containing the endonuclease
Argonaute2(Ago2).Onestrandoftheduplex(theso-called
passenger strand) is removed, while the other remains
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mRNA. For an active duplex, the guide strand is antisense
to the target mRNA, thus the terms guide strand or anti-
sense strand are often used interchangeably.
OTEs commonly arise when the guide RNA directs
RISC to partially complementary sequences within unin-
tended mRNAs, in a fashion similar to the control of gene
expression exerted by endogenous microRNAs (miRNAs)
(5). Still other OTEs can arise when cellular receptors such
as RIG-I, MDA5 and toll-like receptors (TLRs) bind to
siRNAs and trigger innate immune responses, resulting in
cytokine production (6).
A wide variety of nucleotide modiﬁcations can enhance
potency, improve serum stability and reduce OTEs in
certain siRNA sequence contexts (3,4).
We have a long-standing interest in 20-deoxy-
20-ﬂuoroarabinonucleic acid (20F-ANA) (7–11).
20F-ANA is a modiﬁcation that closely mimics DNA
with respect to duplex structure (12), and favors an
eastern sugar conformation (11,13–15). 20F-ANA can
also mimic DNA in its ability to trigger RNase H-
mediated RNA degradation and has applications in anti-
sense technology (16–18). Interestingly, although a
DNA-mimic, 20F-ANA is also compatible and often
stabilizing within a dsRNA context. 20F-ANA has been
successfully incorporated into siRNAs, and is especially
well tolerated in the sense strand which can be fully
20F-ANA modiﬁed with little eﬀect on potency while
enhancing siRNA serum stability (19,20). Given the
DNA-like conformation of 20F-ANA, we hypothesized
that combining 20F-ANA with RNA-like analogs would
further enhance gene silencing potency by forcing A-form
modiﬁed siRNA structures similar to the native siRNA
substrates recognized by RISC. To this end, we chose to
investigate chimeric siRNAs composed of 20F-ANA with
the RNA analogs 20F-RNA and/or locked nucleic acid
(Figure 1).
We designed a large number of modiﬁed duplexes target-
ing two regions of the ﬁreﬂy luciferase gene. Active modi-
ﬁcation designs that emerged from this screen were used to
target the eIF4E-binding proteins 1 and 2 (4E-BP1 and
4E-BP2) using previously reported siRNA sequences
(21).The eukaryotic initiation factor 4F (eIF4F) complex
recognizes mRNA cap structures andfacilitates translation
by recruiting the 43S initiation complex to the mRNA (22).
4EBPs inhibit eIF4F complex assembly by binding eIF4E,
acomponentof theeIF4F complex, preventingtranslation.
It has been reported that 4EBPs are negative regulators
of type-I interferon production because they repress trans-
lation of interferon regulatory factor 7 (IRF-7) mRNA
(23),anessentialtranscriptionfactorforactivationofinter-
feron responses to viral infections (24). Thus, eﬃcient
knockdown of these factors could have beneﬁcial conse-
quences on human health.
MATERIALS AND METHODS
Oligonucleotide synthesis and siRNA preparation
Standard phosphoramidite solid-phase synthesis condi-
tions were used for the synthesis of all modiﬁed and
unmodiﬁed oligonucleotides (25). Syntheses were per-
formed on an Applied Biosystems 3400 DNA
Synthesizer at a 1-mmol scale using Unylink CPG
support (ChemGenes). All phosphoramidites were
prepared as 0.15M solutions in acetonitrile (ACN),
except DNA, which was prepared as 0.1M.
5-ethylthiotetrazole (0.25M in ACN) was used to
activate phosphoramidites for coupling. Detritylations
were accomplished with 3% trichloroacetic acid in
CH2Cl2 for 110s. Capping of failure sequences was
achieved with acetic anhydride in tetrahydrofuran (THF)
and 16% N-methylimidazole in THF. Oxidation was done
using 0.1M I2 in 1:2:10 pyridine:water:THF. Coupling
times were 600s for RNA, 20F-ANA, 20F-RNA, and
LNA (5-methyl C and U) phosphoramidites, with the ex-
ception of their guanosine phosphoramidites which were
allowed to couple for 900s. 50-phosphorylation of chem-
ically modiﬁed antisense strands was achieved using
bis-cyanoethyl-N,N-diisopropyl-2-cyanoethyl
phosphoramidite at 0.15M (600s coupling time).
Deprotection and cleavage from the solid support was ac-
complished with either 3:1 NH4OH:EtOH for 48h at
room temperature (RT), or with 40% methylamine for
10min at 65 C (26). Oligonucleotides containing RNA
were synthesized with standard 20-TBDMS phosphor-
amidites, and desilylation was achieved with either neat
triethylamine trihydroﬂuoride for 48h at RT (27), or
with triethylamine trihydroﬂuoride/N-methyl pyrroli-
done/triethylamine (1.5:0.75:1 by volume) for 2.5h at
65 C (26,28). Puriﬁcation of crude oligonucleotides was
done by preparative denaturing polyacrylamide gel elec-
trophoresis (PAGE) using 24% acrylamide gels. Gel
bands were extracted overnight in DEPC-treated
autoclaved Millipore water, and lyophilized to dryness.
Puriﬁed oligonucleotides were desalted with Nap-25
Sephadex columns from GE Healthcare. Sequences were
veriﬁed by analytical denaturing PAGE and ESI-LCMS.
siRNAs were prepared by annealing equimolar quantities
of complementary oligonucleotides in siRNA buﬀer
[100mM KOAc, 30mM HEPES-KOH, 2mM
Mg(OAc)2, pH 7.4] by slowly cooling from 96 C to RT.
Thermal denaturation and circular dichroism studies
Complementary sequences (1nmol) were combined, dried
and rediluted in pH 7.2 buﬀer (1ml) containing 140mM
KCl, 1mM MgCl2 and 5mM NaHPO4. After heating to
94 C, samples were slowly cooled to RT and refrigerated
overnight. Samples were transferred into cold cuvettes in a
Varian Cary 300UV spectrophotometer. The change in
absorbance at 260nm was monitored upon heating from
10 Ct o9 4  C (ramped at 1 C/min). Melting temperatures
were determined using the baseline method, as imple-
mented in the Cary software.
CD spectra were obtained on a Jasco J-810 spectropo-
larimeter at 20 C using samples annealed in the same
buﬀer and under the same conditions as for the thermal
denaturation studies. Spectra were baseline-corrected
with respect to a blank containing the buﬀer but no
duplex. Smoothing and adjustment for duplex
4548 Nucleic Acids Research, 2010,Vol.38, No. 13concentration were eﬀected using the Spectra-Manager
program (Jasco).
Fetal bovine serum stability assays
Fetal bovine serum (FBS) stability assays were conducted
on unmodiﬁed and modiﬁed siRNAs. siRNAs were
prepared by annealing equimolar amounts of complemen-
tary oligonucleotides as described above with the excep-
tion that water was used instead of siRNA buﬀer. Samples
were then dried, redissolved in 10% FBS (Wisent)
in Dulbecco’s Modiﬁed Eagle Medium (DMEM;
Invitrogen), vortexed and incubated at 37 C. Aliquots
of 0.15 OD units were withdrawn at various times,
ﬂash-frozen on dry ice and stored in the freezer. Extent
of degradation was determined by analytical native
20% PAGE. Bands were visualized by Stains-All
(Sigma-Aldrich).
Luciferase siRNA assays
Fireﬂy luciferase siRNA assays were carried out in HeLa
X1/5 cells stably expressing ﬁreﬂy luciferase, which were
grown as previously described (19). The JG-series
duplexes targeted ﬁreﬂy luciferase mRNA from position
+1818 to+1836 and the ﬀ6 series from+515 to+533. The
day prior to transfection, 0.5 10
5 cells were plated in
each well of a 24-well plate. The next day, the cells were
incubated with increasing amounts of siRNAs premixed
with Lipofectamine-Plus (Invitrogen) using 1mlo f
lipofectamine and 4ml of the Plus reagent per 20pmol of
siRNA (for the highest concentration tested). For the
T   e c n e u q e S   l e b a L m
(
oC)
FF Control 
5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
61.8 
JG-2 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
65.6 
JG-3 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
36.8 
JG-4 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
>90
JG-5 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
72.8 
JG-6 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
62.5 
JG-7 5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-GGCGAACTTCAGAAATTAATTp -5’ 
56.7 
JG-8 5’- GCTTGAAGTCTTTAATTAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
48.2 
JG-9 5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-GGCGAACTTCAGAAATTAATTp -5’ 
45.8 
JG-10  5’- GCTTGAAGTCTTTAATTAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
76.5 
JG-11  5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-GGCGAACTTCAGAAATTAATTp -5’ 
76.2 
JG-12  5’- GCTTGAAGTCTTTAATTAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
64.7 
JG-13  5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-GGCGAACTTCAGAAATTAATTp -5’ 
62.8 
JG-14  5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
80.1 
JG-15  5’- GCTTGAAGTCTTTAATTAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
77.5 
FFC-611  5’- GCUUGAAGUCUUUAAUUAAUU-3’
3’-GGCGAACUUCAGAAAUUAAUUp -5’ 
66.8 
A
B
C
Figure 1. (A) Sequences and thermal denaturation studies of siRNAs targeting ﬁreﬂy luciferase mRNA (the JG series) from position +1818 to
+1836. (B) Activity of siRNAs modiﬁed with 20F-ANA and 20F-RNA (Sequences shown in (A)). mRNA target is ﬁreﬂy luciferase. n=2 for select
siRNAs at the 0.4nM concentration, n=4 for FF Control, JG-4, 6, 8, 11, 12, 14 at the 0.4nM, 2nM, 10nM and 40nM concentrations, n=2 for
JG-2, 3, 5, 7, 9, 10, 13, 15 at the 2nM, 10nM and 40nM concentrations. Fireﬂy luciferase levels were normalized to total cellular protein and
luciferase counts of mock treated cells. Bars indicate standard deviation. (C) Chemical structures of ribonucleic acid (RNA), 20-ﬂuoroarabinonucleic
acid (20F-ANA), 20-ﬂuororibonucleic acid (20F-RNA) and locked nucleic acid (LNA). Legend: RNA, dna, 20F-ANA, 20F-RNA,p = 5 0
phosphorylation.
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[30mM HEPES-KOH, 100mM KOAc, 2mM
Mg(OAc)2, pH 7.4] and the ratio of Lipofectamine-Plus
to siRNA remained constant. Twenty-four hours after
transfection, the cells were lysed in hypotonic lysis buﬀer
(15mM K3PO4, 1mM EDTA, 1% TritonX-100, 2mM
NaF, 1mg/ml BSA, 1mM DTT, 100mM NaCl, 4mg/ml
aprotinin, 2mg/ml leupeptin and 2mg/ml pepstatin) and
the ﬁreﬂy light units were determined using a Fluostar
Optima 96-well plate bioluminescence reader (BMG
Labtech) using ﬁreﬂy substrate as described (29). The
luciferase counts were normalized to the protein concen-
tration of the cell lysate as determined by the DC protein
assay (BioRad). Cotransfecting the siRNAs and the
plasmid pCI-hRL-con expressing the Renilla luciferase
mRNA (30) in the same cell line showed no diﬀerence in
expression of this reporter, suggesting speciﬁcity of the
RNAi eﬀects (data not shown).
4EBP siRNA assays
4EBP siRNA transfections were performed in HEK293T
cells using Lipofectamine Plus reagent on cells plated at
60–70% conﬂuence in 24-well plates. siRNAs were serially
diluted in 100ml Opti-MEM and 1ml Plus reagent
and incubated for 5min at RT. A mixture of 5ml
Lipofectamine and 100ml Opti-MEM was then added to
the precomplexed RNA mix and incubated for 20min at
RT before adding to cells. Five hours later, 500mlo f
complete medium (DMEM with 10% FBS) was added
to the transfection mixture. Cells were harvested 48h
after transfection and proteins were extracted and used
for western blots using antibodies against 4E-BP1 (Cell
Signalling) or 4E-BP2 (Cell Signalling), or Actin (Sigma).
Immunostimulation assays in human peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were trans-
fected using either DOTAP or Lipofectamine 2000 at a
ﬁnal siRNA concentration of 80nM. siRNA (2mlo f
20mM stock) was diluted with 50ml OptiMEM and
combined with 1ml Lipofectamine 2000 in 50ul
OptiMEM then incubated for 20min. For transfection
with DOTAP, siRNA (2ml of 20uM stock) was diluted
with 13ml HEPES-buﬀered saline (HBS) and mixed with
5ml DOTAP in 25ml of HBS, then incubated for 15min.
The mixture was then added to 400ml (Lipofectamine
2000) or 460ml (DOTAP) of cells in culture medium
(RPMI supplemented with 3% FBS) and incubated for
24h. Control (Mock) cells were incubated with lipid
alone. Supernatants (20ml) from untreated or treated
cells were mixed with HEK-Blue cells (Invivogen) in
Hek-Blue detection medium and incubated overnight.
Hek-Blue cells carry a reporter gene expressing a
secreted alkaline phosphatase under the control of the
ISRE9 (interferon stimulated response element 9)
promoter. In response to IFN production, the HEK
blue cells release soluble alkaline phosphatase. The
colored product of the alkaline phosphatase and
Hek-Blue detection medium reaction is quantitated at
650nm. Results are presented as relative IFN units when
background was subtracted. As a positive control for the
assay Hek-Blue cells were incubated with various doses of
puriﬁed interferon a 2b (GeneScript, NJ, USA).
RESULTS AND DISCUSSION
Tuning duplex binding aﬃnity with combinations of
modiﬁcations
We and others have previously shown that 20F-ANA and
20F-RNA adopt diﬀerent preferential conformations
(11,12,31). While both ﬂuorinated analogs have increased
binding aﬃnity to RNA (relative to either DNA or RNA),
combinations of the two can be either stabilizing or
destabilizing depending on how they are combined.
Thus, replacing either strand of an siRNA duplex with
20F-ANA or 20F-RNA increased the duplex Tm value
with respect to the native duplex (Figure 1, duplexes
JG-10–13). In contrast, a 1–1 altimer design signiﬁcantly
decreased duplex stability (Figure 1, duplexes JG-8,9),
possibly arising from the introduction of A/B junctions
within the duplex (12). Chimeric strands with groups
of each modiﬁcation such as JG-2 and JG-6, which
have 20F-ANA purines and 20F-RNA pyrimidines,
contain fewer A/B junctions and exhibit slightly better
stability than the unmodiﬁed siRNA control. A second
set of siRNAs of a diﬀerent sequence, the ﬀ6 series
(Figure 2A), supports these observations.
To further investigate the eﬀects of contrasting con-
formations on duplex stability, we replaced 20F-RNA
inserts with LNA as shown in Figure 3. For these se-
quences, LNAs are ﬂanked by RNA (no A/B junctions)
and/or 20F-ANA (potential A/B junction). However, LNA
is so strongly preorganized that it may inﬂuence ﬂanking
20F-ANA units into an RNA-like conformation (32–34)
and so A/B junctions may be reduced. When LNA is
ﬂanked by 20F-ANA at the 30-end (L-FL 2), eﬀects on
stability are minimal; however, LNA does not increase
duplex stability by the characteristic >3 C typically
observed (35). Alternating 20F-ANA with RNA at the
30-end did reduce stability (L-FL 4).
RNAi activity of modiﬁed siRNAs targeting ﬁreﬂy
luciferase mRNA
We chose a ﬁreﬂy luciferase model system to assess the
activity of our ﬁrst set of chemically modiﬁed siRNAs
(Figure 1A) because it allowed rapid determination of
gene silencing activity. This ﬁrst set of siRNAs
combined 20F-ANA with a well-known RNA analog
used in siRNA, 20F-RNA (36–38). We chemically
50-phosphorylated all 50-modiﬁed antisense strands in
this study, since a 50 phosphate is required for RISC
loading (39) and cellular kinases may not be eﬀective at
phosphorylating modiﬁed nucleosides (20,40). Modiﬁed
sense strands were not chemically phosphorylated, poten-
tially inhibiting sense strand loading into RISC.
Fireﬂy luciferase levels following treatment with
siRNAs at a range of concentrations are shown in
Figure 1B. In Figure 1B, the gene silencing activity of
the full set of siRNAs from Figure 1A are provided.
Many of the chemically modiﬁed siRNAs are of
4550 Nucleic Acids Research, 2010,Vol.38, No. 13equal or greater potency than the unmodiﬁed siRNA (FF
control). The most notable architectures in terms of
potency enhancement are JG-4, 6, 8, 11, 12 and 14, with
JG-6 and 14 being the most potent of the set in this
experiment.
Several trends emerged from this ﬁrst set of siRNA
designs: (i) comparing JG-6 with JG-7 and JG-8 with
JG-9, we inferred that chimeric 20F-ANA/20F-RNA
strands were best used on the sense strand of the
siRNA. (ii) By comparing JG-10 with JG-11, we
observed that a fully 20F-RNA strand works better as an
antisense strand than as a sense strand. In addition, a fully
20F-RNA-modiﬁed siRNA (JG-4) was potent, which has
precedence in at least one other siRNA study (41). (iii)
Comparing JG-12 with JG-13, we observed that
20F-ANA strands work better as the sense strand than
as the antisense strand. Surprisingly, a fully 20F-ANA
modiﬁed duplex (JG-5) had gene silencing activity, albeit
less than the unmodiﬁed siRNA. Based on our observa-
tions of the preferences of 20F-ANA for the sense strand
and 20F-RNA for the antisense strand, JG-14 is expected
to have good gene silencing activity and JG-15 should be
ineﬀective, which was the case.
A major challenge in the development of chemically
modiﬁed siRNA designs is the heavy sequence dependence
exhibited by many chemical modiﬁcations. When a potent
modiﬁcation architecture is identiﬁed for one siRNA
sequence, there is no assurance that the architecture will
be amenable to other siRNA sequences without loss of
potency.
To examine the applicability of our modiﬁcation
designs to a range of targets, we ﬁrst chose to target a
second region of the ﬁreﬂy luciferase mRNA (from+515
to +533) (2) which allowed us to examine the sequence
dependence of our designs. The sequences and architec-
tures tested against this second mRNA region, the ﬀ6
series, are shown in Figure 2A, and their RNAi activity
is illustrated in Figure 2B.
The majority of 20F-ANA/20F-RNA modiﬁcations
tested in this experiment were more potent than the
T   e c n e u q e S   l e b a L m
(
oC)
FF Control 2  5’-  CGUACGCGGAAUACUUCGAtt-3’ 
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
73.3 
ff6-1  5’- CGUACGCGGAAUACUUCGAUU-3’
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
82.2 
ff6-2  5’- CGTACGCGGAATACTTCGATT-3’
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
74.8 
ff6-3  5’-  CGTACGCGGAATACUUCGATT-3’
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
72.5 
ff6-4  5’- CGTACGCGGAAUACTUCGATT-3’
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
72.2 
ff6-5  5’- CGTACGCGGAAUACTUCGATT-3’
3’-ttGCAUGCGCCUUAUGAAGCU  -5’ 
67.9 
ff6-6  5’- CGTACGCGGAAUACTUCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
58.7 
ff6-7  5’- CGUACGCGGAAUACUUCGAUU-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
>85
ff6-8  5’- CGTACGCGGAATACTTCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
>90
ff6-9  5’- CGTACGCGGAATACUUCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
>85
ff6-10  5’- CGTACGCGGAAUACTUCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
>84
ff6-11  5’- CGTACGCGGAAUACTUCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
78.3 
ff6-12  5’- CGTACGCGGAAUACTUCGATT-3’
3’-UUGCAUGCGCCUUAUGAAGCUp -5’ 
69.4 
A B
C
Figure 2. (A) Sequences and thermal denaturation studies of siRNAs targeting ﬁreﬂy luciferase mRNA (the ﬀ6 series) from position+515 to+533.
(B) Assays demonstrating activity of modiﬁed siRNAs. n=2. Fireﬂy luciferase levels were normalized to total cellular protein and luciferase counts
of cells treated with scrambled (non-targeting) siRNAs. (C) Gene silencing assays to directly compare siRNAs targeting the two diﬀerent regions of
luciferase mRNA. The two unmodiﬁed siRNAs were tested, along with ﬀ6-11 and JG-14 modiﬁcation designs. n=2. Fireﬂy luciferase levels were
normalized to total cellular protein and luciferase counts of cells treated with scrambled (nontargeting) siRNA. Bars indicate standard deviation.
Legend: RNA, dna, 20F-ANA, 20F-RNA,p = 5 0 phosphorylation.
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(
oC)
T   e c n e u q e S   l e b a L m
(
oC)
FF Control 
5’-  GCUUGAAGUCUUUAAUUAAtt-3’ 
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
61.8 
L-FL 1  5’- GCuUGAAGUCuUUAAuUAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
61.0 
L-FL 2  5’- GCuUGAAGUCuUUAATuAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
59.2 
L-FL 3  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
58.8 
L-FL 4  5’- GCuUGAAGUCuUUAATUAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
54.9 
L-FL 5  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-ggCGAACUUCAGAAAUUAAUU  -5’ 
59.2 
L-FL 6  5’- GCuUGAAGUCuUUAAuUAATT-3’
3’-GGcGAACUUCAGAAAUUAAUUp -5’ 
65.7 
L-FL 7  5’- GCuUGAAGUCuUUAATuAATT-3’
3’-GGcGAACUUCAGAAAUUAAUUp -5’ 
62.2 
L-FL 8  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-GGcGAACUUCAGAAAUUAAUUp -5’ 
L-FL 9  5’- GCuUGAAGUCuUUAATUAATT-3’
3’-GGcGAACUUCAGAAAUUAAUUp -5’ 
60.5 
L-FL 10  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-GGcGAACUUCAGAAAUUAAUUp -5’ 
61.9 
L-FL 11  5’- GCuUGAAGUCuUUAAuUAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
74.6 
L-FL 12  5’- GCuUGAAGUCuUUAATuAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
73.9 
L-FL 13  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
67.4 
L-FL 14  5’- GCuUGAAGUCuUUAATUAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
71.4 
L-FL 15  5’- GCuUGAAGUCuUUAAUUAATT-3’
3’-GGCGAACTTCAGAAATTAATTp -5’ 
73.0 
Sc 5’-  GCUUGAUUUCUGAAAUUAAtt-3’ 
3’-ggCGAACUAAAGACUUUAAUU  -5’ 
57.0 
A
B
C
Figure 3. (A) Assays demonstrating activity of siRNAs modiﬁed with 20F-ANA, and LNA [sequences shown in (B)]. mRNA target is the ﬁreﬂy
luciferase gene. Fireﬂy luciferase levels were normalized to total cellular protein and average luciferase counts of untreated cells. For 2, 0.4 and
0.08nM concentrations, n=2 (for Sc, L-FL 3, and L-FL4) or n=4 (for FF Control, L-FL 1, 2, 5–10 and untreated cells). n=2 for 0.016, 0.0032,
0.00064nM concentrations. L-FL 3 and 4 were not tested at the bottom three concentrations. (C) Assays demonstrating activity of siRNAs modiﬁed
with 20F-ANA and LNA, with a 20F-RNA antisense stand [sequences shown in (B)]. Fireﬂy luciferase levels were normalized to total cellular protein
and luciferase counts of cells treated with scrambled (nontargeting) siRNA. n=2. Bars indicate standard deviation. Legend: RNA, dna, 20F-ANA,
20F-RNA, lna,p = 5 0 phosphorylation.
4552 Nucleic Acids Research, 2010,Vol.38, No. 13unmodiﬁed control. The lower potency of siRNAs ﬀ6-2
and 3 suggests that fully 20F-ANA sense stands are less
tolerated for this siRNA sequence than the previous one.
Chimeric 20F-ANA/20F-RNA designs, however, retained
their high potency across both sequences. The chimeric
sense strands in ﬀ6-4 and 10 are of a 3–3 altimeric
design, roughly mimicking the sense strands of JG-2 and
6 (which were designed to use 20F-RNA pyrimidines which
are less expensive than purines), but in a manner that can
be used regardless of siRNA sequence. Duplex ﬀ6-8,
which is analogous to JG-14, was more potent than the
unmodiﬁed siRNA in this system as well. The sense strand
of ﬀ6-5 and ﬀ6-11 was designed to take advantage of our
observations that the 1–1 altimer design decreased duplex
stability, but the 20F-ANA purine/20F-RNA pyrimidine
design did not. By placing a 1–1 altimer stretch at the
30-end of the sense strand, we hoped to destabilize the
duplex at the 50-end of the antisense strand and thus
favor loading of the antisense strand into RISC (42,43).
Notably, ﬀ6-11 was the most potent siRNA of this data
set, suggesting our rational design strategy improved
siRNA activity. To further verify our rational design, we
made siRNA FFC-611 (Figure 1A), which targets position
+1818 to+1836 of the ﬁreﬂy luciferase mRNA. As shown
in Supplementary Figure S3, FFC-611 was as potent as
the unmodiﬁed sequence.
These results and previous studies (20) hinted at synergy
between 20F-ANA and northern analogs in siRNA. To
explore whether the synergy between 20F-ANA and
northern nucleotide analogs was general, we replaced the
20F-RNA inserts in our sense strands with LNA, another
northern nucleoside analog with siRNA activity
(36,44–48). Because of the very high binding aﬃnity
increase induced by a single LNA, we used mixtures of
LNA and RNA to replace the 20F-RNA regions of our
duplexes. Figure 3 shows the ﬁve LNA-modiﬁed sense
strands we designed to mimic the sense strand of
JG-2.The ﬁve sense strands were paired with either a
normal RNA antisense strand with DNA overhangs, an
antisense strand with a double 20F-ANA overhang and a
single LNA insert opposite the 50-end of the sense strand
(to favor loading of the correct antisense strand), or a fully
20F-RNA antisense strand. As shown in Figure 3A, these
LNA inserts were also able to produce heavily modiﬁed
siRNAs with potencies equivalent or better than the un-
modiﬁed controls despite heavy chemical modiﬁcation.
We are particularly interested in siRNAs L-FL 6-15,
which have both modiﬁed sense and antisense strands.
L-FL 6-10 have modiﬁcation of the antisense 30-end, pro-
tecting from 30 exonucleases, and L-FL 11-15 have fully
modiﬁed antisense strands for even greater stability.
Combining 20F-ANA with strongly preorganized
northern nucleotides in siRNA duplexes appears to give
a signiﬁcant advantage over RNA itself or combinations
of 20F-ANA with RNA. These improvements may arise
for a number of reasons: (i) heavily modiﬁed siRNAs are
degraded more slowly than unmodiﬁed (or less-modiﬁed)
siRNA; (ii) using the 1–1 altimer design (ﬀ6-5 and ﬀ6-11),
we have lowered the binding aﬃnity at the 30-end of the
sense strand to favor antisense strand loading; (iii) correct
strand loading may be further encouraged by the selective
phosphorylation of the antisense strand combined with
sense strands that are modiﬁed at the 50-end; and (iv) we
may speculate that a subtle structural or dynamic eﬀect is
in operation whereby RISC prefers duplexes that are
A-like but not as rigidly preorganized in the north as
duplexes containing only 20F-RNA or LNA.
Gene silencing activity of modiﬁed siRNAs
targeting 4EBPs
To further determine the scope of application of our
chimeric siRNAs, we decided to target endogenous thera-
peutically relevant genes. The 4E-binding proteins 4E-BP1
and 4E-BP2 repress translation by inhibiting formation of
the eIF4F complex. 4EBPs downregulate interferon pro-
duction by repressing translation of interferon regulatory
factor 7 (23), a transcription factor essential for interferon
responses to viral infections (24). A mouse knockout
of 4E-BP1 and 4E-BP2 showed enhanced immune re-
sponses (23).
We synthesized 20F-ANA/20F-RNA chimeric siRNAs
to target 4E-BP1 and 4E-BP2 in human cells. Eﬀective
siRNA sequences targeting the 4EBPs have been previous-
ly reported in a study examining hepatitis C virus mRNA
translation and replication (21). Two of the most
promising modiﬁed siRNA designs, corresponding to
JG-14 and ﬀ6-11, were selected from our previous
luciferase gene silencing results and used for targeting
4E-BP1 and 4E-BP2 in human (HEK293T) cells (see the
BP series in Table 1 and Supplementary Figure S4).
Levels of 4E-BP2 protein after treating cells with
siRNA are shown in Figure 4 (representative western
blots can be found in Supplementary Figure S6). Both
modiﬁcations designs were very eﬀective at silencing
human 4E-BP2. Both BP2_14 and BP2_611, siRNA
designs derived from JG-14 and ﬀ6-11, were potent
silencing agents for 4E-BP2, with potencies comparable
to the unmodiﬁed siRNA (BP2). 4E-BP2 knockdown
was assayed over a wide range of siRNA concentrations,
from 0.64pM to 250nM. Gene silencing activity became
Table 1. Sequences and thermal denaturation studies of siRNAs
targeting 4E-BP2 mRNA (the BP2 series), and siRNAs used for
studying the eﬀects of modiﬁcation on immunostimulation (the
728 and 728UU series). Legend: RNA, dna, 20F-ANA, 20F-RNA,
p=5 0 phosphorylation
Label Sequence Tm ( C)
BP2 50- AAGACUCCAAAGUAGAAGUaa-30 65.6
30-acUUCUGAGGUUUCAUCUUCA-50
BP2_14 50- AAGACTCCAAAGTAGAAGTAA-30 75.9
30-ACUUCUGAGGUUUCAUCUUCAp-50
BP2_611 50- AAGACUCCAAAGUAGAAGUAA-30 71.0
30-ACUUCUGAGGUUUCAUCUUCAp-50
728 50-AAAUCGCUGAUUUGUGUAG-30 67.1
30-UUUAGCGACUAAACACAUC-50
728UU 50- AAAUCGCUGAUUUGUGUAGUU-30 64.0
30-UUUUUAGCGACUAAACACAUC-50
728 Mod 50-AAAUCGCUGAUUUGUGUAG-30 71.7
30-UUUAGCGACUAAACACAUC-50
728UU Mod 50- AAAUCGCUGAUUUGUGUAGUU-30 71.5
30-UUUUUAGCGACUAAACACAUC-50
Nucleic Acids Research, 2010,Vol.38, No. 13 4553detectable in the 3–80-pM range, and both native and
modiﬁed duplexes had IC50 values in the low nanomolar.
The unmodiﬁed BP2 siRNA was the most potent of the
three, with the BP2_611 and BP2_14 modiﬁed siRNAs
demonstrating only slightly less potency. Gene silencing
experiments against 4E-BP2 included controls in which
cells were treated with a nontargeting, scrambled siRNA
(Sc) and chemically modiﬁed scrambled siRNA
(FFC-611), which were simply selected from our studies
of siRNAs targeting ﬁreﬂy luciferase. The scrambled
controls behaved as expected, exerting little eﬀect on
4E-BP2 gene expression.
Similar results were obtained when we targeted 4E-BP1
with the modiﬁed siRNAs shown in Supplementary
Figure S4. The unmodiﬁed BP1 siRNA was the most
potent of the set, with BP1_611 (an siRNA based on
ﬀ6-11) a close second, followed by BP1_14 (based on
JG-14) which was the least potent but still demonstrated
good gene silencing activity. Results suggest that these
modiﬁcation designs will be widely applicable for silencing
a range mRNA targets.
Immunostimulation
siRNAs can elicit strong interferon-a (IFN-a) responses in
human PBMCs (47,49). To determine if our modiﬁed
siRNAs can reduce non-speciﬁc immunostimulatory
activity in PBMC cells, we treated PBMCs with unmodi-
ﬁed or modiﬁed siRNAs (80nM) and measured IFN pro-
duction 24h later. siRNAs were delivered using DOTAP
(Figure 5). We tested the two sequences used in our
luciferase screen as well as an siRNA sequence previously
reported to have strong immunostimulatory activity in
PBMCs (728UU, and the blunt-ended version, 728) (49).
PBMCs treated with the four unmodiﬁed siRNAs (FF
Control 2, FF Control, 728 and 728UU) showed
signiﬁcantly increased IFN production compared to the
mock treatment (3–7-fold increases were observed). Modi-
ﬁcation of the four sequences based on the ﬀ6-11 design
pattern resulted in immunostimulation levels equivalent to
the negative control measurements. The immuno-
stimulatory proﬁles of the siRNAs were equivalent when
transfected with Lipofectamine 2000 instead of DOTAP
(Supplementary Figure S5A).
Therefore, the immunostimulatory eﬀects of all siRNAs
tested in this experiment can be eradicated by modiﬁcation
with 20F-ANA/20F-RNA. Our LNA constructs have been
less extensively studied, but the results suggest that these
modiﬁcation designs also reduce immunostimulation in
human PBMCs to a similar extent (L-FL 11 and data
not shown).
Circular dichroism studies of 20F-ANA/20F-RNA-modiﬁed
siRNAs
To further characterize the 20F-ANA/20F-RNA-modiﬁed
siRNAs, we utilized circular dichroism (CD) to investigate
the helical structure of modiﬁed siRNAs in the JG series
(Supplementary Figure S2). In general, RNA or
20F-RNA-modiﬁed duplexes were strongly A-form, the
fully 20F-ANA duplex JG-5 was more B-form, and
chimeric duplexes maintained a more A-form conform-
ation. In some cases, we observed signiﬁcant diﬀerences
in CD curves depending on whether equivalent modiﬁca-
tions appear on the sense strand or the antisense strand.
This is in spite of the fact that the purines and pyrimidines
are evenly distributed among the two strands. Thus,
duplex structure is related to the interplay of chemical
modiﬁcations with duplex sequence.
FBS stability assays
Enhanced serum stability is a major advantage of chem-
ically modiﬁed siRNAs. We expected the heavily modiﬁed
nature of many of the 20F-ANA/20F–RNA/LNA
Figure 4. Densitometry analysis of western blot results following
cell treatment with siRNAs modiﬁed with 20F-ANA and 20F-RNA
(sequences shown in Table 1). mRNA target is 4E-BP2 in human
HEK293T cells. siRNA concentrations ranged from 0.00064 to 250
nM. n=10 for Sc 250nM and ScMod 250nM treatments, n=13 for
Mock treatment, n=4 for BP2 0.00064–0.016nM, n=5 for BP2
0.08–250nM, and n=3 for all BP2_14 and BP2_611 treatments.
Representative western blots are shown in Supplementary Figure S6.
Bars represent standard deviation.
Figure 5. IFN levels in PBMC cells 24h after treatment with siRNAs
transfected using DOTAP, as measured by the HEK-Blue IFN assay.
IFN levels in response to unmodiﬁed siRNAs are shown in blue,
modiﬁed siRNAs in green, and control treatments in red. NC is the
negative control (cells alone). Mock treatment was transfection without
siRNA. Data were collected in duplicate for each of two donors.
Results were normalized to the negative control.
4554 Nucleic Acids Research, 2010,Vol.38, No. 13architectures in this report to have signiﬁcant serum sta-
bility, which might play a role in enhancing the potency
and duration of activity of these siRNAs. We compared
the serum stability of the native FF Control duplex with
its fully modiﬁed analog, FFC-611. As shown in
Supplementary Figure S1, the modiﬁed duplex remained
intact for over 1h, and slightly degraded duplex (perhaps
missing only the single-stranded 30 overhangs) was still
observed after 4 days. In contrast, most of the unmodiﬁed
siRNA was degraded within 30min. FBS stability studies
on heavily modiﬁed 20F-ANA–RNA chimeric siRNAs,
under similar conditions to the ones used here, have
been previously described (19). In the previous study,
20F-ANA–RNA chimeric siRNAs had a serum half-life
of about 5h. Results shown in Supplementary Figure S1
are in agreement with stability experiments of 20F-ANA–
RNA chimeric siRNAs, and suggest that siRNAs made of
20F-ANA and 20F-RNA are even more stable than those
made of 20F-ANA and RNA.
CONCLUSIONS
siRNAs that contain combinations of 20F-ANA with the
rigid RNA analogs 20F-RNA or LNA show superior
properties to native duplexes or duplexes with these modi-
ﬁcations alone. Each of these nucleoside analogs has pre-
viously been used for siRNA-mediated gene silencing, but
to the best of our knowledge, this is the ﬁrst report of
chimeric siRNAs composed of combinations of these
modiﬁcations. Our results show knockdown of several
genes with high potency, surpassing even the native
duplexes in some cases. Furthermore, dramatically
reduced immunostimulatory activity and excellent serum
stability was observed.
Previous work by Ui-Tei et al. (50) showed that com-
binations of DNA and RNA gave siRNAs with potent
silencing ability and reduced OTEs. The reduction in
OTEs observed by these chimeric siRNAs was attributed
in part to the lower binding aﬃnity at the DNA-rich
50-end of the duplex (50). Our results are similar in at
least two respects: (i) we show that combining analogs
of DNA and RNA imparts superior properties to
siRNAs than are obtained by either analog taken alone;
and (ii) we also attribute part of this success to the lower
binding aﬃnity at the 50-end of the duplex. However,
many diﬀerences exist between the two designs. For
example, where Ui-Tei et al. used stretches of dsDNA to
reduce OTEs, we propose a region of alternating nucleo-
tides with diﬀerent conformations in one strand.
Furthermore, their duplexes are entirely constructed
from native DNA and RNA, while ours are mostly or
entirely made of modiﬁed nucleotides. Thus, the two
designs may have diﬀerent strengths and diﬀerent
spheres of application.
Several heavily modiﬁed siRNA designs have been
reported recently (19,20,41,51–55), a few of which are
entirely devoid of RNA. The sequence dependence of
many of these architectures has yet to be fully determined.
Our results indicate that siRNAs fully modiﬁed with
rational combinations of 20F-ANA, 20F-RNA and/or
LNA are advantageous gene silencing agents with a
broad range of applications.
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